- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06744920
Um estudo para investigar a eficácia, segurança e tolerabilidade do remibrutinibe versus placebo em pacientes adultos com miastenia gravis generalizada (RELIEVE)
Um estudo de fase III randomizado, duplo-cego e controlado por placebo para avaliar a eficácia, segurança e tolerabilidade do remibrutinibe em pacientes com miastenia gravis generalizada, seguido por uma fase de extensão aberta
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants will be randomized in a ratio of 1:1, to receive either remibrutinib or matching placebo.
The study consists of a Core Part (6-months double-blind treatment) and an Extension Part (up to 60-month open-label treatment).
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Gummersbach, Alemanha, 51643
- Novartis Investigative Site
-
Hamburg, Alemanha, 20246
- Novartis Investigative Site
-
Münster, Alemanha, 48149
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Alemanha, 60590
- Novartis Investigative Site
-
-
-
-
-
Buenos Aires, Argentina, C1012AAR
- Novartis Investigative Site
-
Caba, Argentina, C1055AAF
- Novartis Investigative Site
-
Capital Federal, Argentina, C1023AAB
- Novartis Investigative Site
-
San Miguel de Tucumán, Argentina, T4000AXL
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Novartis Investigative Site
-
-
-
-
Victoria
-
Fitzroy, Victoria, Austrália, 3065
- Novartis Investigative Site
-
-
-
-
-
São Paulo, Brasil, 05403-000
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 40050-410
- Novartis Investigative Site
-
-
Federal District
-
Brasília, Federal District, Brasil, 70200-730
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Caxias do Sul, Rio Grande do Sul, Brasil, 95070-560
- Novartis Investigative Site
-
Porto Alegre, Rio Grande do Sul, Brasil, 90480-110
- Novartis Investigative Site
-
-
-
-
Ontario
-
London, Ontario, Canadá, N6A 5W9
- Novartis Investigative Site
-
Ottawa, Ontario, Canadá, K1H 8L6
- Novartis Investigative Site
-
-
Quebec
-
Québec, Quebec, Canadá, G1J 1Z4
- Novartis Investigative Site
-
-
-
-
-
Beijing, China, 100730
- Novartis Investigative Site
-
Beijing, China, 100034
- Novartis Investigative Site
-
Qingdao, China, 266000
- Novartis Investigative Site
-
Shanghai, China, 200080
- Novartis Investigative Site
-
Shanghai, China, 200040
- Novartis Investigative Site
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Novartis Investigative Site
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050030
- Novartis Investigative Site
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Novartis Investigative Site
-
-
Jiangsu
-
Wuxi, Jiangsu, China, 214023
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Novartis Investigative Site
-
-
-
-
-
Busan, Coréia do Sul, 49241
- Novartis Investigative Site
-
Seoul, Coréia do Sul, 03080
- Novartis Investigative Site
-
Seoul, Coréia do Sul, 03722
- Novartis Investigative Site
-
Seoul, Coréia do Sul, 05278
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Espanha, 08035
- Novartis Investigative Site
-
Lleida, Espanha, 25198
- Novartis Investigative Site
-
Madrid, Espanha, 28034
- Novartis Investigative Site
-
Málaga, Espanha, 29010
- Novartis Investigative Site
-
Valencia, Espanha, 46026
- Novartis Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85013
- Neuromuscular Research Center
-
Scottsdale, Arizona, Estados Unidos, 85258
- Honor Health Research Institute
-
-
California
-
Fullerton, California, Estados Unidos, 92835
- Fullerton Neuro and Headache Ctr
-
Los Angeles, California, Estados Unidos, 90033
- University Of Southern California
-
Sacramento, California, Estados Unidos, 94115
- California Pacific Medical Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010-2975
- Medstar Washington Hospital Center
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33487
- SFM Clinical Research LLC
-
Homestead, Florida, Estados Unidos, 33033
- Homestead Assoc In Research Inc
-
Maitland, Florida, Estados Unidos, 32751
- Neurology Associates PA
-
Orlando, Florida, Estados Unidos, 32804
- AdventHealth
-
Orlando, Florida, Estados Unidos, 32806
- Neurological Services of Orlando PA
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Medical Centr
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20817-1807
- Mid Atlantic Epilepsy and Sleep Ctr
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
Michigan
-
East Lansing, Michigan, Estados Unidos, 48824
- Michigan State University-Department of Neurology
-
-
New York
-
Buffalo, New York, Estados Unidos, 14209
- Dent Neurological Institute
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- University of Pittsburgh Medical Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Houston Methodist Hospital
-
Houston, Texas, Estados Unidos, 77030
- UT Health Science Center
-
San Antonio, Texas, Estados Unidos, 78229-3900
- University of Texas Health Science Center at San Antonio
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- University of WA Division of Cardio
-
-
Wisconsin
-
Greenfield, Wisconsin, Estados Unidos, 53228-1321
- Center for Neurological Disorders G
-
-
-
-
-
Bordeaux, França, 33076
- Novartis Investigative Site
-
Nice, França, 06000
- Novartis Investigative Site
-
Paris, França, 75013
- Novartis Investigative Site
-
Paris, França, 75940
- Novartis Investigative Site
-
Strasbourg, França, 67081
- Novartis Investigative Site
-
Toulouse, França, 31059
- Novartis Investigative Site
-
-
-
-
-
Kutaisi, Geórgia, 4600
- Novartis Investigative Site
-
Tbilisi, Geórgia, 0114
- Novartis Investigative Site
-
Tbilisi, Geórgia, 0144
- Novartis Investigative Site
-
-
-
-
North Holland
-
Amsterdam, North Holland, Holanda, 1105 AZ
- Novartis Investigative Site
-
-
-
-
BG
-
Bergamo, BG, Itália, 24127
- Novartis Investigative Site
-
-
TO
-
Orbassano, TO, Itália, 10043
- Novartis Investigative Site
-
-
-
-
-
Chiba, Japão, 2608677
- Novartis Investigative Site
-
Fukuoka, Japão, 8128582
- Novartis Investigative Site
-
Fukushima, Japão, 9601295
- Novartis Investigative Site
-
Hiroshima, Japão, 7348551
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japão, 0630005
- Novartis Investigative Site
-
Sapporo, Hokkaido, Japão, 0608543
- Novartis Investigative Site
-
-
Hyōgo
-
Nishinomiya, Hyōgo, Japão, 6638501
- Novartis Investigative Site
-
-
Iwate
-
Hanamaki, Iwate, Japão, 0250082
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Japão, 9838520
- Novartis Investigative Site
-
-
Osaka
-
Suita, Osaka, Japão, 5650871
- Novartis Investigative Site
-
-
Saitama
-
Higashi-Matsuyama, Saitama, Japão, 3550005
- Novartis Investigative Site
-
Koshigaya, Saitama, Japão, 3438555
- Novartis Investigative Site
-
-
Tokyo
-
Shinjuku Ku, Tokyo, Japão, 1600023
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japão, 1608582
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz, Polônia, 85-065
- Novartis Investigative Site
-
Katowice, Polônia, 40-689
- Novartis Investigative Site
-
Lodz, Polônia, 93-113
- Novartis Investigative Site
-
Lublin, Polônia, 20-701
- Novartis Investigative Site
-
Lublin, Polônia, 20-410
- Novartis Investigative Site
-
Poznan, Polônia, 61-731
- Novartis Investigative Site
-
Skorzewo, Polônia, 60-185
- Novartis Investigative Site
-
Warsaw, Polônia, 01-684
- Novartis Investigative Site
-
Warsaw, Polônia, 02-172
- Novartis Investigative Site
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polônia, 20-064
- Novartis Investigative Site
-
Lublin, Lublin Voivodeship, Polônia, 20-080
- Novartis Investigative Site
-
-
POL
-
Krakow, POL, Polônia, 31-505
- Novartis Investigative Site
-
-
-
-
-
London, Reino Unido, SW17 0QT
- Novartis Investigative Site
-
-
-
-
-
Brasov, Romênia, 500283
- Novartis Investigative Site
-
Bucharest, Romênia, 040215
- Novartis Investigative Site
-
Sibiu, Romênia, 550245
- Novartis Investigative Site
-
-
-
-
-
Belgrade, Sérvia, 11000
- Novartis Investigative Site
-
Niš, Sérvia, 18108
- Novartis Investigative Site
-
Novi Sad, Sérvia, 21000
- Novartis Investigative Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Novartis Investigative Site
-
Tainan, Taiwan, 704302
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
Taipei, Taiwan, 111045
- Novartis Investigative Site
-
Taoyuan, Taiwan, 33305
- Novartis Investigative Site
-
-
-
-
Haryana
-
Gurugram, Haryana, Índia, 122011
- Novartis Investigative Site
-
-
Karnataka
-
Mangalore, Karnataka, Índia, 575002
- Novartis Investigative Site
-
-
Maharashtra
-
Nashik, Maharashtra, Índia, 422005
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Índia, 110029
- Novartis Investigative Site
-
-
Punjab
-
Ludhiana, Punjab, Índia, 141001
- Novartis Investigative Site
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Índia, 632004
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, Índia, 500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Índia, 226007
- Novartis Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adult patients with gMG (age 18-85 years)
- Confirmed diagnosis of Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG at screening and likely not in need of a respirator for the duration of the study, as judged by the Investigator
- Documented evidence of positive serologic testing for AChR+ antibody or MuSK+ antibody at screening, OR seronegative for both AChR and MuSK antibodies at screening
- Baseline MG-ADL score ≥ 6 with ≥ 50% of the total score due to non ocular symptoms
- Participants who have been receiving a standard-of-care treatment as specified in the protocol
- Able to safely swallow the study medication according to investigator clinical judgement based on a bedside swallowing test or another formal swallowing test in line with local practice, both at Screening and Baseline
Exclusion Criteria:
- Prior to baseline have been treated with intravenous immunoglobulins or plasma exchange (IVIg/PLEX) in the past month, with rituximab in the past 6 months, eculizumab in the past 2 months, ravulizumab or other complement inhibitors in the past 3 months, efgartigimod or other anti-FcRn therapies in the past 3 months, or had a thymectomy in the past 6 months or a planned thymectomy during the trial period
- Women of child bearing potential, defined as all women physiologically capable of becoming pregnant, from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping of study treatment
Other protocol-defined inclusion/exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Remibrutinib arm
Core Part: Remibrutinib tablet taken orally [Extension Part: Open-label remibrutinib tablet taken orally] |
Remibrutinib (Blinded) active treatment
Outros nomes:
Remibrutinib (Open Label) active treatment
Outros nomes:
|
|
Comparador de Placebo: Placebo arm
Core Part: Placebo tablet taken orally [Extension Part: Open-label remibrutinib tablet taken orally] |
Placebo Remibrutinib (Open Label) active treatment
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score
Prazo: Baseline to Month 6
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Baseline to Month 6
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline to Month 6 in Quantitative Myasthenia Gravis (QMG) total score
Prazo: Baseline to Month 6
|
The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item). |
Baseline to Month 6
|
|
Proportion of participants with ≥ 5 points reduction from baseline to Month 6 of QMG total score without rescue medication and/or strongly confounding prohibited medication
Prazo: Baseline to Month 6
|
The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item). |
Baseline to Month 6
|
|
Proportion of participants with ≥ 3 points reduction from baseline to Month 6 of Myasthenia Gravis Activity of Daily Living (MG-ADL) scale total score without rescue medication and/or strongly confounding prohibited medication
Prazo: Baseline to Month 6
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Baseline to Month 6
|
|
Proportion of participants achieving Minimal Symptom Expression (MSE) at Month 6, defined as MG-ADL score of 0 or 1 at Month 6 without rescue therapy and/or strongly confounding prohibited medication
Prazo: Month 6
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Month 6
|
|
Change from baseline to Month 6 in Myasthenia Gravis Composite score (MGC) total score
Prazo: Baseline to Month 6
|
The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments. |
Baseline to Month 6
|
|
Change from baseline to Month 6 in revised Myasthenia Gravis Quality of Life Questionnaire (MG-QOL15r) survey score
Prazo: Baseline to Month 6
|
The revised MG-QoL15 is a 15-item health related quality of life questionnaire completed by participants, designed to measure quality of life in gMG. Items on the MG-QoL15 relate to physical, social, and psychological components and are scored from 0 (not at all) to 2 (very much). The cumulative scores range from 0 to 30, with higher scores representing worse quality of life and dissatisfaction with MG-related dysfunction. |
Baseline to Month 6
|
|
Incidence of adverse events
Prazo: Baseline to Month 6
|
Incidence of adverse events including changes in clinical laboratory values, vital signs, electrocardiograms and suicidality results qualifying and reported as AEs. |
Baseline to Month 6
|
|
Proportion of time during which participants showed a reduction of ≥ 2 points in MG-ADL total score, that was maintained up to Month 6
Prazo: Baseline to Month 6
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Baseline to Month 6
|
|
Proportion of early MG-ADL responders during treatment (early responders with first MG-ADL improvement from baseline of ≥ 2 points occurring by week 4)
Prazo: Baseline to week 4
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). Participants with a first MG-ADL improvement from baseline of ≥ 2 points occurring by week 4 are considered early responders. |
Baseline to week 4
|
|
Change from baseline to Month 6 in EuroQol-5 Dimensions-5 Level (EQ-5D-5L)
Prazo: Baseline to Month 6
|
The EQ-5D-5L is a widely used questionnaire designed to assess health status in adults. The measure is divided into two distinct sections, the descriptive system and the EQ visual analogue scale (EQ VAS). The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Participants rate each of these items from 1 of the 5 levels: no problems, slight problems, moderate problems, severe problems, or unable to/extreme. A composite health state is then defined by combining the levels for each dimension into a 5-digit number. The second section includes the EQ visual analogue scale (EQ VAS) that measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best imaginable health state" and 0 represents the "worst imaginable health state." Respondents are asked to rate their current health by placing a mark along this continuum. |
Baseline to Month 6
|
|
Proportion of participants achieving a reduction from baseline of ≥ 3 points in MGC total score at Month 6
Prazo: Baseline to Month 6
|
The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments. |
Baseline to Month 6
|
|
Change from baseline in MG-ADL total score
Prazo: Baseline to Month 66
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Baseline to Month 66
|
|
Change from baseline in QMG total score
Prazo: Baseline to Month 66
|
The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item). |
Baseline to Month 66
|
|
Change from baseline in MGC total score
Prazo: Baseline to Month 66
|
The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments. |
Baseline to Month 66
|
|
Proportion of participants achieving a reduction from core part in oral corticosteroids (OCS) dose till the end of extension part
Prazo: Baseline to month 66
|
Participants receiving oral corticosteroids are required to be on a stable dose for at least 4 weeks prior to baseline. The dose can be reduced or discontinued during the open label extension period at investigator discretion. Oral corticosteroids use will be recorded. |
Baseline to month 66
|
|
Incidence of adverse events
Prazo: Month 7 to month 66
|
Incidence of adverse events including changes in clinical laboratory values, vital signs, electrocardiograms and suicidality results qualifying and reported as AEs. |
Month 7 to month 66
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Neoplasias por local
- Neoplasias
- Doenças Neuromusculares
- Doenças autoimunes
- Doenças do sistema imunológico
- Doenças Autoimunes do Sistema Nervoso
- Doenças Neurodegenerativas
- Síndromes Paraneoplásicas do Sistema Nervoso
- Neoplasias do Sistema Nervoso
- Síndromes Paraneoplásicas
- Doenças da Junção Neuromuscular
- Miastenia grave
- RUNIBRUTINIB
Outros números de identificação do estudo
- CLOU064O12301
- 2023-510026-32 (Outro identificador: EU CTIS)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .